MCID: NNL001
MIFTS: 41

Non-Langerhans-Cell Histiocytosis

Categories: Rare diseases, Immune diseases

Aliases & Classifications for Non-Langerhans-Cell Histiocytosis

MalaCards integrated aliases for Non-Langerhans-Cell Histiocytosis:

Name: Non-Langerhans-Cell Histiocytosis 12 53 15
Histiocytosis, Non-Langerhans-Cell 76 53 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4330
MeSH 44 D015616
SNOMED-CT 68 127069007
UMLS 73 C0019624

Summaries for Non-Langerhans-Cell Histiocytosis

MalaCards based summary : Non-Langerhans-Cell Histiocytosis, also known as histiocytosis, non-langerhans-cell, is related to juvenile xanthogranuloma and reticulohistiocytic granuloma. An important gene associated with Non-Langerhans-Cell Histiocytosis is CD163 (CD163 Molecule), and among its related pathways/superpathways are Lysosome and Cholesterol and Sphingolipids transport / Distribution to the intracellular membrane compartments (normal and CF). The drugs Etoposide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and testes, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 76 Non-Langerhans cell histiocytosis refers to a family of histiocytosis characterized by the absence of... more...

Related Diseases for Non-Langerhans-Cell Histiocytosis

Diseases related to Non-Langerhans-Cell Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Related Disease Score Top Affiliating Genes
1 juvenile xanthogranuloma 32.7 BRAF DES F13A1
2 reticulohistiocytic granuloma 32.0 CD163 CD207
3 fibromatosis 30.4 ACTC1 DES
4 fibroblastic rheumatism 30.1 ACTC1 CD163 DES F13A1
5 langerhans cell histiocytosis 29.9 BRAF CD163 CD207 F13A1
6 histiocytosis 28.8 BRAF CD163 CD207 IL1RN SMPD1
7 erdheim-chester disease 11.7
8 histiocytosis, progressive mucinous 11.3
9 progressive nodular histiocytosis 10.8 ACTC1 F13A1
10 scleromyxedema 10.8 ACTC1 F13A1
11 ovarian fibrothecoma 10.7 ACTC1 DES
12 cutaneous leiomyosarcoma 10.7 ACTC1 DES
13 botryoid rhabdomyosarcoma 10.7 ACTC1 DES
14 spindle cell lipoma 10.7 ACTC1 DES
15 parachordoma 10.7 ACTC1 DES
16 myofibroma 10.7 DES F13A1
17 ossifying fibromyxoid tumor 10.7 ACTC1 DES
18 epithelioid leiomyosarcoma 10.7 ACTC1 DES
19 benign metastasizing leiomyoma 10.7 ACTC1 DES
20 congenital fibrosarcoma 10.7 ACTC1 DES
21 pulmonary vein stenosis 10.7 ACTC1 DES
22 cystic nephroma 10.6 ACTC1 DES
23 niemann-pick disease type c, severe perinatal form 10.6 NPC1 NPC2
24 niemann-pick disease type c, late infantile neurologic onset 10.6 NPC1 NPC2
25 pleomorphic liposarcoma 10.6 ACTC1 DES
26 niemann-pick disease type c, severe early infantile neurologic onset 10.6 NPC1 NPC2
27 niemann-pick disease type c, adult neurologic onset 10.6 NPC1 NPC2
28 ischemic fasciitis 10.6 ACTC1 DES
29 niemann-pick disease type c, juvenile neurologic onset 10.6 NPC1 NPC2
30 binswanger's disease 10.6 ACTC1 SST
31 perivascular epithelioid cell tumor 10.6 ACTC1 DES
32 reticulum cell sarcoma 10.6 ACTC1 DES
33 dedifferentiated liposarcoma 10.6 ACTC1 DES
34 glomus tumor 10.6 ACTC1 DES
35 spindle cell sarcoma 10.6 ACTC1 DES
36 pseudosarcomatous fibromatosis 10.6 ACTC1 DES
37 acid sphingomyelinase deficiency 10.6 NPC1 SMPD1
38 rhabdoid cancer 10.5 ACTC1 DES
39 smooth muscle tumor 10.5 ACTC1 DES
40 myopericytoma 10.5 ACTC1 BRAF
41 infantile myofibromatosis 10.5 ACTC1 DES
42 adenofibroma 10.4 ACTC1 BRAF
43 angiolipoma 10.4 ACTC1 DES F13A1
44 chondromyxoid fibroma 10.4 ACTC1 DES
45 villous adenoma 10.4 BRAF SST
46 hemangiopericytoma, malignant 10.4 ACTC1 DES F13A1
47 malignant fibroxanthoma 10.4 ACTC1 DES F13A1
48 dermatofibrosarcoma protuberans 10.4 ACTC1 DES F13A1
49 fasciitis 10.4 ACTC1 DES
50 lipogranulomatosis 10.3

Graphical network of the top 20 diseases related to Non-Langerhans-Cell Histiocytosis:



Diseases related to Non-Langerhans-Cell Histiocytosis

Symptoms & Phenotypes for Non-Langerhans-Cell Histiocytosis

MGI Mouse Phenotypes related to Non-Langerhans-Cell Histiocytosis:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.15 PITX3 SMPD1 NPC2 SST IL1RN CD163
2 cardiovascular system MP:0005385 10.13 PITX3 NPC2 IL1RN CD163 NPC1 DES
3 cellular MP:0005384 10.11 PITX3 SMPD1 NPC2 BRAF IL1RN CD163
4 behavior/neurological MP:0005386 10.1 PITX3 NPC1 SMPD1 SST NPC2 HEXA
5 growth/size/body region MP:0005378 10.09 PITX3 NPC1 SMPD1 SST NPC2 HEXA
6 hematopoietic system MP:0005397 10.06 PITX3 SMPD1 NPC2 BRAF IL1RN CD163
7 immune system MP:0005387 9.97 PITX3 SMPD1 SST NPC2 BRAF IL1RN
8 mortality/aging MP:0010768 9.85 SMPD1 SST NPC2 BRAF IL1RN NPC1
9 liver/biliary system MP:0005370 9.73 PITX3 NPC1 SMPD1 NPC2 HEXA BRAF
10 reproductive system MP:0005389 9.5 PITX3 NPC1 SMPD1 HEXA BRAF IL1RN
11 respiratory system MP:0005388 9.17 PITX3 SMPD1 NPC2 CD163 NPC1 F13A1

Drugs & Therapeutics for Non-Langerhans-Cell Histiocytosis

Drugs for Non-Langerhans-Cell Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 131)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 3,Phase 2,Not Applicable 33419-42-0 36462
2
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
3
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
4
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
5
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Not Applicable 50-18-0, 6055-19-2 2907
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-02-2 5743
8
Busulfan Approved, Investigational Phase 3,Phase 2,Not Applicable,Early Phase 1 55-98-1 2478
9
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
10
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
11
Miglustat Approved Phase 3,Phase 2,Phase 1 72599-27-0 51634
12
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
13
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
14
Pegaspargase Approved, Investigational Phase 3 130167-69-0
15
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-30-3 6037
17
Butyric Acid Experimental, Investigational Phase 3,Phase 2 107-92-6 264
18
Doxil Approved June 1999 Phase 3,Phase 2 31703
19
1-Deoxynojirimycin Experimental Phase 3,Phase 2 19130-96-2 1374
20 Dexamethasone acetate Phase 3,Phase 2,Not Applicable 1177-87-3
21 Alkylating Agents Phase 3,Phase 2,Not Applicable
22 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
23 Folic Acid Antagonists Phase 3,Phase 2,Not Applicable
24 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 Cortisol succinate Phase 3,Phase 2
26 Cyclosporins Phase 3,Phase 2,Phase 1,Not Applicable
27 Topoisomerase Inhibitors Phase 3,Phase 2,Not Applicable
28 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
29 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
31 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
33 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2
34 Hydrocortisone acetate Phase 3,Phase 2
35 Hydrocortisone-17-butyrate Phase 3,Phase 2
36 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Anti-Bacterial Agents Phase 3,Phase 2
38 Vitamin B Complex Phase 3,Phase 2,Not Applicable
39 Antibiotics, Antitubercular Phase 3,Phase 2
40 Etoposide phosphate Phase 3,Phase 2,Not Applicable
41 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Not Applicable
43 Antiemetics Phase 3,Phase 2,Phase 1,Not Applicable
44 Antifungal Agents Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Antilymphocyte Serum Phase 3,Phase 2,Not Applicable
47 Antitubercular Agents Phase 3,Phase 2
48 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 BB 1101 Phase 3,Phase 2,Not Applicable
50 Antimetabolites Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis Unknown status NCT00334672 Phase 3 busulfan;cyclophosphamide;cyclosporine;dexamethasone;etoposide;methotrexate;mycophenolate mofetil;therapeutic hydrocortisone
2 Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 Completed NCT00426101 Phase 3 Dexamethasone;Etoposide;Cyclosporin
3 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
4 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
5 DEP-Ru Regimen as a Salvage Therapy for HLH Recruiting NCT03533790 Phase 3 DEP-Ru
6 L-DEP as an Initial Treatment for EBV-HLH Recruiting NCT02912702 Phase 3 Pegaspargase;doxorubicin hydrochloride liposome injection;etoposide;methylprednisolone;Etoposide;dexamethasone
7 Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology Recruiting NCT02862054 Phase 2, Phase 3
8 L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis Recruiting NCT02631109 Phase 3 Pegaspargase;doxorubicin;etoposide;methylprednisolone
9 A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis Recruiting NCT01818492 Phase 2, Phase 3
10 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
11 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
12 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
13 Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis Not yet recruiting NCT03312751 Phase 3 Emapalumab
14 T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
15 Trial of DA-EPOCH Regimen for NHL With HLH Unknown status NCT01818908 Phase 2 DA-EPOCH
16 Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis Completed NCT01104025 Phase 2 ATG, rabbit;Etoposide;Methotrexate;hydrocortisone;Dexamethasone
17 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
18 Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) Completed NCT01998633 Phase 2
19 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
20 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
21 Miglustat in Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
22 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
23 Treatment of Familiar Lymphohistiocytosis Recruiting NCT02472054 Phase 1, Phase 2 Alemtuzumab;Methyl Prednisolone (MP);Cyclosporin A (CSA)
24 Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Recruiting NCT02385110 Phase 2 Alemtuzumab;Etoposide;Dexamethasone;Methotrexate;Tocilizumab
25 Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Recruiting NCT02007239 Phase 2 tocilizumab
26 Busulfan, Fludarabine, and Thiotepa Conditioning Regimen for Non Malignant Disease Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
27 Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C Recruiting NCT03471143 Phase 1, Phase 2 2-Hydroxypropyl-Beta-Cyclodextrin
28 A Study to Investigate the Safety and Efficacy of an Anti-IFN-gamma mAb in Children With Systemic Juvenile Idiopathic Arthritis (sJIA) Developing Macrophage Activation Syndrome/ Secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH) Recruiting NCT03311854 Phase 2 NI-0501
29 Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease Recruiting NCT03201627 Phase 1, Phase 2 Lithium Carbonate
30 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
31 Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1 Recruiting NCT02912793 Phase 1, Phase 2 Hydroxypropyl-beta-cyclodextrin
32 Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency Recruiting NCT02292654 Phase 1, Phase 2 Olipudase alfa
33 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2 Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
34 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Recruiting NCT00368355 Phase 2 Ara-C;Cyclophosphamide
35 A Study of Lenalidomide for Adult Histiocyte Disorders Active, not recruiting NCT02523040 Phase 2 Lenalidomide
36 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
37 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Enrolling by invitation NCT02004704 Phase 2 GZ402665
38 Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease Suspended NCT02281760 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
39 Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease Terminated NCT01727206 Phase 2 Tocilizumab
40 Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Terminated NCT00668564 Phase 2 Cyclophosphamide;Campath-1H;Busulfan
41 Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease Completed NCT01747135 Phase 1 VTS-270
42 Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients Completed NCT01722526 Phase 1 Recombinant human acid sphingomyelinase
43 Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease Completed NCT00316498 Phase 1 OGT918
44 Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1) Recruiting NCT02939547 Phase 1 Hydroxypropyl-beta-cyclodextrin
45 UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Recruiting NCT02254863 Phase 1
46 BMT Abatacept for Non-Malignant Diseases Recruiting NCT01917708 Phase 1 Abatacept
47 Human Placental-Derived Stem Cell Transplantation Active, not recruiting NCT01586455 Phase 1 Human Placental Derived Stem Cell
48 Administration of Donor T Cells With the Caspase-9 Suicide Gene Active, not recruiting NCT01494103 Phase 1 AP1903
49 Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases Terminated NCT02231710 Phase 1
50 Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Terminated NCT00410566 Phase 1 rhASM;rhASM;rhASM;rhASM;rhASM

Search NIH Clinical Center for Non-Langerhans-Cell Histiocytosis

Cochrane evidence based reviews: histiocytosis, non-langerhans-cell

Genetic Tests for Non-Langerhans-Cell Histiocytosis

Anatomical Context for Non-Langerhans-Cell Histiocytosis

MalaCards organs/tissues related to Non-Langerhans-Cell Histiocytosis:

41
T Cells, Skin, Testes, Bone Marrow, Liver, Eye, Brain

Publications for Non-Langerhans-Cell Histiocytosis

Articles related to Non-Langerhans-Cell Histiocytosis:

(show all 27)
# Title Authors Year
1
A Rare Case of Erdheim-Chester Disease (Non-Langerhans Cell Histiocytosis) with Concurrent Langerhans Cell Histiocytosis: A Diagnostic and Therapeutic Challenge. ( 29888013 )
2018
2
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. ( 28679734 )
2017
3
Non-Langerhans cell histiocytosis. ( 26739442 )
2016
4
Spontaneous regression of infantile dural-based non-Langerhans cell histiocytosis after surgery: case report. ( 25634822 )
2015
5
[Erdheim-Chester disease and Rosai-Dorfman disease: Pathological, radiological and clinical features of adult non-Langerhans cell histiocytosis]. ( 26305142 )
2015
6
Suprasellar non-Langerhans cell histiocytosis (Erdheim-Chester disease)--a case report. ( 23465991 )
2013
7
Retinal manifestations in a patient with xanthoma disseminatum (non-langerhans cell histiocytosis). ( 21484660 )
2011
8
Rare case of infratentorial non-Langerhans cell histiocytosis with lethal outcome presenting multiple diagnostic difficulties. ( 22025140 )
2011
9
Non-Langerhans cell histiocytosis with isolated CNS involvement: an unusual variant of Erdheim-Chester disease. ( 20337948 )
2010
10
Intracranial non-Langerhans cell histiocytosis presenting as an isolated intraparenchymal lesion. ( 20635081 )
2010
11
Fibroblastic rheumatism: fibromatosis rather than non-Langerhans cell histiocytosis. ( 19615014 )
2010
12
Endolymphatic non-langerhans cell histiocytosis of the larynx: report of an uncommon disease manifestation. ( 20463609 )
2010
13
Non-Langerhans cell histiocytosis in a child with Kawasaki disease. ( 21686403 )
2009
14
Diffuse xanthogranulomatous dermatitis and systemic Langerhans cell histiocytosis: A novel case that demonstrates bridging between non-Langerhans cell histiocytosis and Langerhans cell histiocytosis. ( 19022530 )
2009
15
Cerebral non-Langerhans cell histiocytosis in a 17-year-old patient with a headache: case report. ( 19363626 )
2009
16
Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. ( 16020507 )
2005
17
[Erdheim-Chester disease: a non-Langerhans cell histiocytosis. A clinical-case and review of the literature]. ( 15344569 )
2004
18
Progressive histiocytosis: description of a case of slow-course non-Langerhans cell histiocytosis. ( 12399681 )
2002
19
Problems in differential diagnosis of non Langerhans cell histiocytosis with pituitary involvement: case report and review of literature. ( 12665654 )
2002
20
A child with both Langerhans and non-Langerhans cell histiocytosis. ( 12383099 )
2002
21
Primary cerebral non-Langerhans cell histiocytosis: MRI and differential diagnosis. ( 12221448 )
2002
22
Benign cephalic histiocytosis progressing into juvenile xanthogranuloma: a non-Langerhans cell histiocytosis transforming under the influence of a virus? ( 10698221 )
2000
23
Non-Langerhans cell histiocytosis associated with lymphocyte-predominant Hodgkin's disease. ( 10564322 )
1999
24
Generalized non-Langerhans cell histiocytosis: four cases illustrate a spectrum of disease. ( 7737766 )
1995
25
An unusual case of non-Langerhans cell histiocytosis. ( 8294600 )
1994
26
A unique non-Langerhans cell histiocytosis with some features of generalized eruptive histiocytoma. ( 8034797 )
1994
27
Congenital self-healing non-Langerhans cell histiocytosis. ( 3058480 )
1988

Variations for Non-Langerhans-Cell Histiocytosis

Expression for Non-Langerhans-Cell Histiocytosis

Search GEO for disease gene expression data for Non-Langerhans-Cell Histiocytosis.

Pathways for Non-Langerhans-Cell Histiocytosis

Pathways related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.01 HEXA NPC1 NPC2 SMPD1
2
Show member pathways
10.1 NPC1 NPC2

GO Terms for Non-Langerhans-Cell Histiocytosis

Cellular components related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.8 ACTC1 DES HEXA IL1RN NPC1 NPC2
2 extracellular region GO:0005576 9.7 CD163 F13A1 IL1RN NPC1 NPC2 SMPD1
3 lysosome GO:0005764 9.26 HEXA NPC1 NPC2 SMPD1
4 lysosomal lumen GO:0043202 8.8 HEXA NPC2 SMPD1

Biological processes related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 muscle filament sliding GO:0030049 9.4 ACTC1 DES
2 response to cocaine GO:0042220 9.37 PITX3 SMPD1
3 cholesterol transport GO:0030301 9.32 NPC1 NPC2
4 cholesterol efflux GO:0033344 9.26 NPC1 NPC2
5 response to drug GO:0042493 9.26 ACTC1 NPC1 SMPD1 SST
6 low-density lipoprotein particle clearance GO:0034383 9.16 NPC1 NPC2
7 establishment of protein localization to membrane GO:0090150 8.62 BRAF NPC1

Sources for Non-Langerhans-Cell Histiocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....